Pharmaceuticals Mexico

Mexico Dengue Vaccines Market Analysis, 2024–2034

Mexico Dengue Vaccines Market Industry Trends and Forecast to 2034: Segmented by (Product, Age, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Mexico · 2024–2034 · estimates

Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $10.1 Mn Estimated value
Estimate 2025 $12.2 Mn 1.7% of the global market
Projected 2034 $65.9 Mn 439.7% Adds $53.7 Mn over 9 forecast years
CAGR 2025–2034 20.6% Faster than 89% of 180 Pharmaceuticals markets here
Key players 5
  • Mexico is 1.7% of the global market.
  • In Latin America, the largest is Brazil at $20.7 Mn.
  • Fastest growing: Brazil at 21.3% a year.
  • Mexico ranks 3rd of 3 by size in Latin America.

Market size projection

Mexico

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$53.7 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Dengue Vaccines Market market size by year, Mexico
YearMarket sizeChange that yearSince 2025
2024 (estimate) $10.1 Mn — —
2025 (base) $12.2 Mn +$2.1 Mn —
2026 (forecast) $14.7 Mn +$2.5 Mn +20.6%
2027 (forecast) $17.8 Mn +$3.0 Mn +45.4%
2028 (forecast) $21.4 Mn +$3.7 Mn +75.4%
2029 (forecast) $25.8 Mn +$4.4 Mn +111.5%
2030 (forecast) $31.2 Mn +$5.3 Mn +155.1%
2031 (forecast) $37.6 Mn +$6.4 Mn +207.7%
2032 (forecast) $45.3 Mn +$7.7 Mn +271%
2033 (forecast) $54.7 Mn +$9.3 Mn +347.5%
2034 (forecast) $65.9 Mn +$11.3 Mn +439.7%

Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

The Mexico Dengue Vaccines Market Analysis Executive Summary

Dengue vaccines protect against dengue fever, a mosquito-borne disease spreading fast in tropical and warming regions.

Key segments of the dengue Vaccines market include product (Live Attenuated Vaccines and Candidate Vaccines) and age (Children, Adolescents and Adults).

Mexico Dengue Vaccines Market Dynamics

Market Growth Drivers

Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the dengue Vaccines market.

Opportunity

New vaccines, rapid tests and public-private funding for neglected diseases give the dengue Vaccines market room to grow, especially in Asia, Africa and Latin America.

Market Restraints

Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the dengue Vaccines market.

Competitive Landscape for Dengue Vaccines Market in Mexico

The dengue Vaccines market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Dengue Vaccines Market in Mexico

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for dengue Vaccines. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Mexico.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Dengue Vaccines right now, from free public sources.

Clinical trials

2 active trials in Mexico

Recruiting, about to start, or running now.

Top trial sponsors (worldwide)

  1. Takeda Pharmaceutical Company Ltd 5 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Sanofi 2 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Dengue Vaccines in context

Mexico compared

  • Health spending per person: 761 US$ per person (2023). World: 1,317 US$ per person (2023). 2nd highest of the 4 countries we cover in Latin America.[1]
  • Doctors: 2.59 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). Highest of the 4 countries we cover in Latin America.[2]
  • People aged 65 and over: 8.5% of people (2025). World: 10.4% of people (2025). 3rd highest of the 4 countries we cover in Latin America.[3]

Questions, answered with public data

How many clinical trials on Dengue Vaccines are running in Mexico?
2 studies are recruiting, active or about to start in Mexico.[4]
How much research is published on Dengue Vaccines?
PubMed lists 165 papers added since January 2021 that match this market, worldwide.[5]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 13 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 13 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 13 Nov 2026.

[4] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Mexico. Retrieved 12 Nov 2026.

[5] PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.

Free data on this topic

Back to Catalogue

Related Pharmaceuticals reports in Mexico

See all

Related on vaccines and infectious diseases

See the topic